Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc (RPRX) director Bonnie L. Bassler acquired 642 Class A Ordinary Shares on September 30, 2026, under the 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Her direct holdings following the award were 79,823 shares.
Royalty Pharma plc (RPRX) EVP, Research & Investments Marshall Urist sold 4,126 Class A Ordinary Shares on September 28, 2026, at $57.88 per share under a Rule 10b5-1 plan adopted June 26, 2026. After the sale, he reported 4,126 shares held directly and 19,020 shares held indirectly through an IRA.
Separately, Urist and family vehicles controlled by him reported limited partnership interests exchangeable into 2,444,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd. exchangeable into 1,356,528 Class A Ordinary Shares. The Class E Ordinary Shares are subject to vesting conditions.
Royalty Pharma plc (RPRX) lists Officer Marshall Urist's proposed sale of 4,126 Class A ordinary shares, with an aggregate market value of $238,812.88 and Merrill Lynch named as broker. The shares are identified as an equity performance award granted by Royalty Pharma on August 5, 2026; the notice lists September 28, 2026, as the sale date. Shares outstanding were 445,277,344 as of September 28, 2026.
At Royalty Pharma plc, EVP & Chairman, Partnering Christopher Hite reported that SCH Investment Partners LLC sold 100,000 Class A ordinary shares on September 22, 2026: 96,073 at a weighted average $58.5148 per share and 3,927 at $58.9261. The sales were made under a Rule 10b5-1 plan adopted March 20, 2026. Hite held 23,200 shares directly after the transactions; family vehicles also hold interests exchangeable into 866,410 Class A ordinary shares and Class E shares exchangeable into 1,238,789 Class A ordinary shares, with vesting conditions applying to the Class E shares.
Royalty Pharma plc (RPRX) received a notice that SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares under Rule 144 through Merrill Lynch. The proposed sale has an approximate aggregate market value of $5,846,972.43, compared with 445,277,344 Class A Ordinary Shares outstanding. SCH Investment Partners LLC previously sold 350,000 Class A Ordinary Shares during the past three months under a Rule 10b5-1(c) selling plan dated March 20, 2026.
Royalty Pharma plc (RPRX) reported insider activity by Christopher Hite, EVP & Chairman, Partnering. An entity associated with him, SCH Investment Partners LLC, sold 100,000 Class A Ordinary Shares at a weighted average price of $59.9725 per share pursuant to a Rule 10b5-1 trading plan, leaving 370,401 indirectly held shares. Separately, Hite made a charitable gift of 16,800 Class A Ordinary Shares to Lehigh University, after which he directly held 23,200 shares. Family vehicles also hold exchangeable interests and Class E shares that are convertible into additional Class A Ordinary Shares, some of which are subject to vesting conditions.
Royalty Pharma plc (RPRX) received a notice that SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares of Royalty Pharma under Rule 144. These shares, acquired in private transactions in 2024 and 2025, have an aggregate market value of $6,012,000. Royalty Pharma had 445,277,344 shares outstanding as of the notice date. SCH Investment Partners LLC previously sold 150,000 shares for $8,166,766.13 on June 23, 2026 and 100,000 shares for $5,645,700.97 on June 30, 2026, all under a selling plan dated March 20, 2026 intended to comply with Rule 10b5-1(c).
Royalty Pharma plc major shareholder Pablo Legorreta filed an amended beneficial ownership report updating his holdings in the company’s Class A ordinary shares. Pablo Legorreta is reported as beneficially owning 101,785,843 Class A Shares, representing 18.73% of the class, including 96,873,648 shares that may be issued under an A&R Exchange Agreement. Legorreta Investments, LLC is reported as beneficially owning 37,535,019 Class A Shares, representing 7.76%, including 37,074,880 shares that may be issued under the same agreement. These percentages are calculated based on 446,619,215 Class A Shares outstanding as of August 13, 2026, plus shares issuable pursuant to the A&R Exchange Agreement.
The filing explains that SEC rules attribute beneficial ownership to persons with sole or shared voting or investment power and include Class A Shares issuable upon conversion or exercise of other securities that are immediately, or within 60 days, convertible or exercisable. It also describes recent equity-related activity, including the settlement of equity performance awards and a bona fide gift of partnership interests exchangeable into Class A Shares.
Royalty Pharma plc EVP & CFO Terrance P. Coyne, through entity TPC RP EPA1 LLC, reported selling a total of 11,002 Class A Ordinary Shares of RPRX on August 13, 2026 in open-market or private transactions under a Rule 10b5-1 plan adopted on February 24, 2026. The sales comprised 9,230 shares at a weighted average price of $58.5864 (with individual trades between $57.99 and $58.98) and 1,772 shares at a weighted average price of $59.1415 (with trades between $58.98 and $59.52). Following these transactions, indirect holdings reported include 24,170 shares in a spouse’s IRA, 23,270 shares in the reporting person’s IRA, and 1,450 shares held by the spouse, plus 1,500 shares held directly. In addition, the reporting person and related family vehicles hold interests exchangeable into 6,448,180 Class A Ordinary Shares via limited partnership interests in RPI US Partners 2019, LP and 1,788,777 Class A Ordinary Shares via Class E Ordinary Shares of Royalty Pharma Holdings Ltd, which are subject to vesting conditions.
TPC RP EPA1 LLC, an affiliate stockholder of Royalty Pharma plc (symbol RPRX), filed a notice of proposed sale of 11,002 shares of common stock through Goldman Sachs & Co. LLC. The shares were acquired on 08/05/2026 as compensation under performance awards from the issuer.
The filing also lists a prior transaction in the last three months, where TPC RP EPA1 LLC sold 64,399 shares of common stock on 05/26/2026 for an aggregate amount of $3,476,118.96.